key: cord-0766466-m3twxrkw
authors: Jin, D. K.; Nesbitt, D. J.; Yang, J.; Chen, H.; Horowitz, J.; Jones, M.; Vandergaast, R.; Carey, T.; Reiter, S.; Russell, S. J.; Kyratsous, C.; Hooper, A.; Hamilton, J.; Ferreira, M.; Deng, S.; Straus, D.; Baras, A.; Hillyer, C. D.; Luchsinger, L. L.
title: Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of New York City Metro Blood Donors using Multiple SARS-CoV-2 Serological Assays: Implications for Controlling the Epidemic and Reopening.
date: 2020-11-07
journal: nan
DOI: 10.1101/2020.11.06.20220087
sha: af9db52bf2f2a3597f26a785c52894295eeb80d9
doc_id: 766466
cord_uid: m3twxrkw

Projections of the stage of the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) pandemic and local, regional and national public health policies designed to limit the spread of the epidemic as well as reopen cities and states, are best informed by reproducible, high throughput, and statically credible antibody (Ab) assays. To date, a myriad of Ab tests, both available and authorized for emergency use by the FDA, has led to confusion rather than insight per se. The present study reports the results of a rapid, point-in-time 1,000-person cohort study using serial blood donors in the New York City metropolitan area (NYC) using multiple serological tests, including enzyme-linked immunosorbent assays (ELISAs) and high throughput serological assays (HTSAs). These were then tested and associated with assays for neutralizing Ab (NAb). Of the 1,000 NYC blood donor samples in late June and early July 2020, 12.1% and 10.9% were seropositive using the Ortho Total Ig and the Abbott IgG HTSA assays, respectively. These serological assays correlated with neutralization activity specific to SARS-CoV-2. The data reported herein suggest that seroconversion in this population occurred in approximately 1 in 8 blood donors from the beginning of the pandemic in NYC (considered March 1, 2020). These findings deviate with an earlier seroprevalence study in NYC showing 13.7% positivity. Collectively however, these data demonstrate that a low number of individuals have serologic evidence of infection during this first wave and suggest that the notion of herd immunity at rates of ~60% or higher are not near. Furthermore, the data presented herein show that the nature of the Ab-based immunity is not invariably associated with the development of NAb. While the blood donor population may not mimic precisely the NYC population as a whole, rapid assessment of seroprevalence in this cohort and serial reassessment could aid public health decision making.

The Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 pandemic has swept the global community with the United States reporting nearly 8.5 million confirmed cases and over 230,000 deaths from 48 Coronavirus disease (COVID)-19.(1, 2) Transmission models of SARS-CoV-2, supported by studies of 49 immune responses to related viral infections, suggest that recovery from infection could provide immunity to 50 reinfection.(1, 3) Thus, the use of serological tests to identify those who have acquired antibodies (Abs) 51 against SARS-CoV-2 (seroconversion) and the frequency of seroconversion in the population (seroprevalence) 52 is a powerful means with which to guide public health policies.(4, 5) The term 'hotspots' has emerged to 53 describe regions of high infectivity that appear and then recede as the pandemic evolves. It is important to 54 ascertain the frequency of SARS-CoV-2 seropositivity in regional populations to estimate the risk of infection 55 associated with newly developing or receding COVID-19 hotspots. 56 As natural infection continues to persist, and vaccine distribution commences, serologic assays will be 57 vital in monitoring the development of herd immunity, also called community or population immunity, which 58 refers to the point at which enough people are sufficiently "protected", and person-to-person transmission is 59 unlikely. Reaching this milestone will, in effect, herald the end of the COVID-19 pandemic. Therefore, 60 population-wide serological assessment and reassessment are critical, and the tests employed need to be 61 reliable, credible, reproducible and high throughput. Furthermore, it is important to understand the degree of 62 correlation of any given assay's "reactivity" with the presence of neutralizing antibody (Nab). These data, 63 then, can be used to assist public health officials in modeling projections and in informing policy making 64 decisions including the safe "reopening" of cities, states, and regions. 65 The performance and sensitivity of COVID-19 serology assays is myriad in platform (lateral flow, 66 ELISA, etc.) and variable in terms of sensitivity and specificity.(6, 7) Such assays rely on detection and 67 quantification of antibodies that recognize specific SARS-CoV-2 antigens including the four major structural CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi. org/10.1101 org/10. /2020 recovered individuals produced the strongest immunogenic antibodies against antigens of the S and N 72 proteins.(9) Thus, the development of serological tests for SARS-CoV-2 antibodies has focused heavily on the 73 detection of antibodies against these viral proteins.

As above, antibody-based tests vary considerably in both technology (platform) and target antigen 75 (design) which led to, in May 2020, the FDA reversing its emergency use authorization (EUA) and approval 76 policies in order to help ensure that reliable tests could be used to accurately measure seroconversion in 77 populations. Some tests have received emergency use authorization but population-wide data are limited, and 78 continuous monitoring is necessary to be of practical importance.

Variability in test characteristics, particularly sensitivity, implies that there may not yet be an ideal test 80 design and instrument platform, which can lead to variability and potential bias in the estimation of the level 81 of immunity in various locales or subpopulations.(10, 11) However, two platforms have been widely cited: 1) 82 in-house enzyme linked immunosorbent assays (ELISA), and 2) high-throughput serological assays (HTSA).

ELISAs offer wide flexibility for research laboratories to select virtually any antigenic protein of interest and 84 assay patient sera to provide highly sensitive, quantitative results. HTSAs are more suitable to clinical 85 laboratories processing large volumes of samples. Although HTSAs offer a narrower selection of antigen 86 choices, these platforms offer high-throughput capacity, high sensitivity and can be integrated into clinical lab 87 testing facilities. The resulting expectation of antibody development is an association with antiviral activity 88 and acquisition of immunity against future viral infection. However, only a subset of virus-specific antibodies 89 will be neutralizing, and the levels of SARS-CoV-2-specific neutralizing antibodies necessary to confer 90 protective immunity following infection or vaccination across the population are not known. Thus, studies that 91 evaluate serological test designs are necessary to associate a serological result with a probability of immunity.

New York City (NYC) was one of the first epicenters of the COVID-19 pandemic and possesses the 93 highest case count per capita of anywhere in the United States.(12) Seroconversion, therefore, is likely to be 94 substantial in a random sampling of NYC residents. Moreover, the true number of COVID-19 cases may be 95 underreported, resulting in inaccurate case estimates (incidence) and morbidity and mortality rates of SARS-96 CoV-2. (13) 97 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 surrogate for the population as a whole, an indicator of the stage of the epidemic, and as a baseline for future 100 reassessments, using commercially available serology tests, and characterize the Ab responses in ELISAs and 101 a neutralizing antibody assays, allowing us to ultimately inform city, state and nation-wide efforts to mitigate 102 the pandemic and its attendant social and economic strife.

To estimate seroprevalence, 1,000 blood donor plasma samples were randomly collected from NYBC 106 blood donation centers between June and July 2020, encompassing regions proximal to NYC, including Long 107 Island, Westchester County and New Jersey ( Figure 1A) . To characterize donors demographically, we cross-108 referenced donor data to the 2010 U.S. Census dataset.(14) Donors ranged in age from 16 to 78 years with a 109 median age of 48 years (95% CI: 46-49 years), which was older than the New York City median age of 35.5 110 years and deviated from a Gaussian distribution ( Figure 1B , r 2 =0.708). The donor group also included 111 significantly fewer female donors (38.5%) compared to 52.5% citywide ( Figure 1C ). Donors that did not 112 respond to ethnicity or reported as 'Other' composed 15.6% of the donors. Among donors that responded, the 113 distribution of donor race/ethnicity was 73% white, 3.6% black, 3.4% multi-race, and 4.4% Asian, compared 114 to an average NYC Metro distribution of 44% white, 25.55% black, 3.99% multi-race, and 12.7% Asian 115 ( Figure 1D ). These data show skewing of blood donors from the NYC demographics in many categories, 116 which is a known characteristic of the blood donor population.

To quantify SARS-CoV-2 seroprevalence in donor samples, the Ortho Clinical Diagnostics VITROS 119 Total Ig Test (Ortho) and the Abbott Labs Architect SARS-CoV-2 IgG (Abbott) HTSA assays were used. (Figure 2A) . Adjusting for sample size effect, the estimated seroprevalence rate using the Ortho HTSA was 122 12.1% (95% CI: 10.2 -14.27%) while the Abbott test indicates a seroprevalence rate was 10.9% (95% CI:

123 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101/2020.11.06.20220087 doi: medRxiv preprint positive for anti-SARS-CoV-2 antibodies using both the Ortho and Abbott tests, and 19 (14.84%) or 7 (5.47%) 125 of donors testing positive using only the Ortho or Abbott test, respectively ( Figure 2B ). The median results Figure 2D ).

The gold-standard of serological quantification is the ELISA assay. To compare HTSA results using 133 our in-house SARS-CoV-2 ELISA assays, we analyzed donor plasma for antibodies using S1 and NP 134 antigens. Using the S1 ELISA ( Figure 2E ), the median value for seropositive donors was 352.1 µg/mL 135 (n=128, 95% CI: 312.0-399.8 µg/mL, IQR: 179.9 -617.2 µg/mL) and the median value for negative donors 136 was 21.5 µg/mL (n=97, 95% CI: 17.32 -26.77 µg/mL, IQR: 6.29 -38.79 µg/mL). Using the NP ELISA 137 (Figure 2F ), the median value for seropositive donors was 193.5 ng/mL (n=128, 95% CI: 155.6 ng/mL-138 226.7ng/mL, IQR: 74.00 ug/mL-380 ug/mL) and the median value for negative donors was 19.38 ng/mL 139 (n=97, 95% CI: 15.74 ng/mL -24.20 ng/mL, IQR: 12.79 ug/mL -31.49ug/mL). Interestingly, seropositive 140 donors for Ortho and Abbott tests showed 88.2% and 84.5% above the S/co value for the S1 ELISA assay.

Expectedly, seropositive donors negative by S1 ELISA assays had relatively low HTSA scores (data not 142 shown), which suggests HTSA assays have higher sensitivity than traditional ELISA methodology. Linear 143 regression of Ortho and Abbott tests ( Figure 2G ) showed a modest goodness-of-fit (r 2 =0.37) indicating that 144 while HTSA test scores are positively associated, a high degree of variation within donors exists between 145 HTSA test results. Taken together, these data confirm that a wide range of serological results are prevalent in 146 the NYC metro population and HTSA platforms have the highest sensitivity to quantify serological results 147 with which to estimate seroprevalence.

Neutralizing Activity of NYC Blood Donors 149 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101/2020.11.06.20220087 doi: medRxiv preprint form of immunity to future viral exposure; particularly in relation to effective vaccination. In the case of 151 SARS-CoV-2, such assays require biosafety level 3 (BSL-3) facilities and highly trained personnel. To 152 overcome this limitation and expedite testing, we employed a 'surrogate virus' neutralization assay to quantify 153 nAb levels present in donor plasma, which differs from conventional SARS-CoV-2 pseudovirus particles in 154 that surrogate virus retains replication potential and is thus more analogous to live SARS-CoV-2. The results 155 of the neutralization end point titer (NT100) assays are summarized in Table 1 Table 2) . These data 164 illustrate the that serological assays, particularly those with values near the S/co value for each assay, may not 165 reliably correspond to bona fide neutralization activity.

The semi-quantitative NT100 method showed that titers for seropositive samples varied between donors.

Reciprocal dilution factor values ranged from <80 to 1,280 ( Figure 3A) . Analysis of the 128 seropositive 168 samples revealed 21.9% were below the LOD at the 1:80 dilution (the lowest dilution tested in this analyses) 169 and 7.0% were considered 'indeterminant', due to suspected sample interference. We found low NT100 titers of 170 80 and 160 comprised 30.5% and 29.7% of BD samples, respectively, constituting over half of seropositive 171 blood donors. Moderate NT100 titers of 320 and 640 accounted for 5.5% and 4.7% of donors while the highest 172 nAb titers of ≥1280 described 0.8% of seropositive samples. These data indicate that, similar to serology 173 results, nAb levels against SARS-CoV-2 are highly variable and are skewed towards low neutralizing activity 174 within seropositive blood donors in the NYC metro area.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101/2020.11.06.20220087 doi: medRxiv preprint scale of the general population. While many serology tests have been developed, evidence as to the predictive 177 value between SARS-CoV-2 serology test results and neutralizing activity continues to be an important 178 validation for the medical and scientific community. To this end, we examined the correlation between Abbott: r=0.62), followed by the S1 (r=0.55) and NP (r=0.51). Interestingly, the Ortho HTSA and S1 ELISA, 183 and Ortho HTSA and nAb assay showed the highest correlation (r=0.64), further validating the SARS-CoV-2 184 spike S1 protein as an important target of neutralizing function. These data confirm that established HTSA and 185 ELISA assays strongly correlate with neutralizing activity. As expected, the Ortho test, which measures anti-186 spike antibodies, showed a higher degree of correlation with the S1 ELISA titers (r=0.639) while the Abbot 187 test, which measures anti-NP antibodies, showed a high degree of correlation with the NP ELISA titer 188 (r=0.778).

Further, median values for both HTSA assays increased with higher neutralizing assay titers (Figure 3B, 3C ) 190 and this observation was also observed in ELISA assays (Figure 3D, 3E) . These data highlight the utility of 191 HTSA and ELISA assays to predict neutralization activity of plasma samples. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101/2020.11.06.20220087 doi: medRxiv preprint test result and blood donation is not known, CP eligibility requires that the donor be 14 days from the date of 202 last symptom. Whether or not indeterminate/negatives may have seroconverted subsequent to the donation 203 analyzed, these results show strong correlation between positive SARS-CoV-2 PCR test results, seropositivity, 204 and neutralization activity and may be suggestive of longitudinal immunity.

COVID-19 antibody testing has entered public discourse as an important metric in monitoring the 207 evolution of the SARS-CoV-2 outbreak. Ultimately, the application of antibody testing could be clinically 208 informative as to the degree of immunity incurred by recovered patients or vaccinated individuals. Random 209 blood donor screening is a practice that is readily feasible using blood banking infrastructure to rapidly screen 210 regional populations for seroprevalence monitoring. This is the first study to evaluate a large cohort of 211 random blood donors in the NYC metro area for SARS-CoV-2 antibodies. However, we recognize the 212 limitations of the current study include a lack of generalizability as a consequence of the modestly skewed 213 demographics of blood donors and the general population as a whole, and that this may impact the 214 conclusions of the results. In fact, seroprevalence has been suggested to be higher in specific racial/ethnic 215 communities based on recent studies.(15) Thus, more inclusive and complete seroprevalence studies will need 216 to be performed in the future. Nonetheless, the authors believe that using blood donor in serial studies is an 217 important, if indirect, measure of community immunity.

In this study, we found the Ortho Total Ig and Abbott IgG HTSA assays estimate a ~10.9-12.2% 219 SARS-CoV-2 seroprevalence in July of 2020 in the NYC Metro area. Moreover, we found that ELISA assays, 220 which are the gold-standard of serological quantification, corresponded with seropositive classification of 221 donors as detected by HTSAs, thus validating the use of ELISAs in population studies. Further, in seropositive 222 blood donors we observed a wide range of anti-SARS-CoV-2-neutralizing activity that was skewed towards 223 low to moderate NT100 titers. This trend is in agreement with our previous investigation of convalescent 224 plasma donors(16) and a study of patients recovering from COVID-19, both of which also showed large 225 variability and modest levels of neutralizing activity in plasma units. (17) 226 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101/2020.11.06.20220087 doi: medRxiv preprint from state and local departments of health. Seroconversion in a study of Bergen County, NJ was estimated to 228 be 12.2% in June of 2020.(18) Seroconversion among hospital workers in New York City was estimated to be 229 13.7% as of June of 2020. (19) The overall seroprevalence in New York City, at the peak of the epidemic, was 230 estimated to be 21% with some communities as high as 68% using data from emergency care clinics. (20) In conclusion, we estimate the seroprevalence of NYC metro blood donors to be approximately 1 in 8 238 donors during the month of July 2020 and four months post the commencement of the epidemic in NY. While 239 it is slightly lower than another study using a NYC population of healthcare workers during a similar time 240 period, who, in all likelihood, had higher than typical exposure rates,(19) our findings demonstrate a 241 comparable seroprevalence estimate can be discerned using a widely accessible blood donor population and it 242 an important metric during this catastrophic outbreak. This strategy can therefore be leveraged in its design for 243 future studies to implement rapid seroconversion/seroprevalence monitoring. Furthermore, considering the 244 possibility that this may be an underestimate of the metropolitan population, these conclusions suggest that in 245 the absence of a vaccine, "background" or "herd" immunity continues to be low at four months post-246 commencement, and, now eight months into the US pandemic, it is probable that the susceptible population 247 remains very high, and possibly at ~80% or greater. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi. org/10.1101 org/10. /2020 From June 16, 2020 -July 15, 2020, consecutive NYC metro donors (n=1,000) received a 2-question 253 survey, provided demographic information and completed a blood donation. Choropleth was generated in 254 house from donor zip code prefix data using the web tool, http://www.heatmapper.ca/geocoordinate/. Plasma 255 was isolated from whole blood samples collected in citrate tubes. Samples were extracted, aliquoted to 256 minimize freeze-thaw cycles, and stored at -80°C. Donor blood samples were tested using the Ortho 257 VITROS™ SARS-CoV-2 Total Ig assay, Abbott SARS-CoV-2 IgG assay, in-house ELISAs, and the Vyriad 258 IMMUNO-COV™ neutralization assay as described with some modifications.(23) The IMMUNO-COV 259 assay performed here differed from that which was described in the referenced publication in that: 1) plasma 260 samples were heat-inactivated instead of serum samples, which is necessary due to thermal coagulation and 2) 261 neutralization activity was quantified using neutralization end point titer (NT100) method and not a standard 276 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10. 1101 Flat-well, nickel-coated 96 well ELISA plates (Thermo Scientific; USA) were coated with 2 ug/mL of 278 recombinant S1 spike protein, nucleocapsid protein, or Receptor Binding Domain (RBD) spike protein 279 specific to SARS-CoV-2 in resuspension buffer (1% Human Serum Albumin in 0.01% TBST) and incubated 280 in a stationary humidified chamber overnight at 4°C. On the day of the assay, plates were blocked for 30 min 281 with ELISA blocking buffer (3% W/V non-fat milk in TBST). Standard curves for both S1 and RBD assays CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 managed the collection of data, figures and statistical analyses. LLL, JH, AB and CDH co-wrote the 302 manuscript.

Acknowledgements 305 We thank Jill Alberigo, Amanda Brites and Kelly Brightman from Rhode Island Blood Center for their help 306 with performing the Ortho Anti-SARS-CoV-2 Total Test and the Abbott SARS-CoV-2 IgG test.

The authors declare no conflicts of interest. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101 https://doi.org/10. /2020 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101/2020.11.06.20220087 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101/2020.11.06.20220087 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101/2020.11.06.20220087 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10.1101/2020.11.06.20220087 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 7, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 7, 2020. ; https://doi.org/10. 1101 

The proximal origin of SARS-CoV-2

A new coronavirus associated with human 382 respiratory disease in China

Early dynamics of transmission and 384 control of COVID-19: a mathematical modelling study

Examination of seroprevalence of coronavirus 386 HKU1 infection with S protein-based ELISA and neutralization assay against viral spike pseudotyped virus

Serological Approaches for COVID-19: Epidemiologic Perspective on 389 Surveillance and Control

York City COVID19 Convalescent Plasma Donors. medRxiv. 2020

COVID19 antibody detection using lateral 393 flow assay tests in a cohort of convalescent plasma donors

B-cell responses in patients who have recovered from 395 severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein

Characterization of the receptor-binding domain (RBD) 398 of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Efficacy of Serology Testing in Predicting Reinfection in 401 Patients with SARS-CoV-2

Antibody tests for 403 identification of current and past infection with SARS-CoV-2. Cochrane

Lachmann A. Correcting under-reported COVID-19 case numbers. medRxiv. 2020. 407 14. USCensusBureau. 2010 Census of Population and Housing on Summary Population and Housing 408 Characteristics. United States Government Printing Office

SARS-CoV-2 Positivity Rate for 410 Latinos in the

Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID19 Patients

Evaluating the Association of Clinical Characteristics With 414 Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in

Prevalence of SARS-CoV-2 Antibodies 419 in Health Care Personnel in the New York City Area

Million Antibody Tests Show What Parts of N.Y.C. Were Hit Hardest. The New York Times

Rhode Island Blood Donors Determined using Multiple Serological Assay Formats. medRxiv. 2020

Longitudinal observation and decline of 425 neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Development and validation of 427 IMMUNO-COV: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2. bioRxiv

Interval Estimation for a Binomial Proportion